Belgian chemical company Solvay is investing an undisclosed sum in Invizius, a UK biotech start-up that is developing a proprietary anti-inflammatory solution for hemodialysis. The spin-out of Edinburgh University will use the funds to complete a First-in-Man safety study of its H-Guard Priming anti-inflammatory product, which is designed to address the side effects of dialysis and other extra-corporeal treatments.